Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients-Reference-Cited by-同舟云学术

Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients

Published:2009-09 Issue:13 Volume:45 Page:2312-2315
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fiebrich Helle-Brit,Brouwers Adrienne H.,Koopmans Klaas Pieter,de Vries Elisabeth G.E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies;Gerstle;J Am Coll Surg,1995

2. Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer;de Groot;Ann Surg Oncol,2004

3. Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-l-DOPA;De Vries;Appl Radiat Isot,1999

4. Fluorine-18-fluoro-l-DOPA dosimetry with carbidopa pretreatment;Brown;J Nucl Med,1998

5. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis;Ishikawa;J Cereb Blood Flow Metab,1996

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy;Nuclear Medicine Communications;2016-04

2. Other Radiopharmaceuticals for Imaging GEP-NET;Somatostatin Analogues;2015-06-05

3. La TEP des tumeurs neuroendocrines de l’intestin grêle;Médecine Nucléaire;2014-09

4. Other PET Tracers for Neuroendocrine Tumors;PET Clinics;2014-01

5. 18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type;European Journal of Nuclear Medicine and Molecular Imaging;2013-02-16